Literature DB >> 30656520

Chinese guidelines on the management of ascites and its related complications in cirrhosis.

Xiaoyuan Xu1, Zhongping Duan2, Huiguo Ding3, Wengang Li4, Jidong Jia5, Lai Wei6, Enqiang Linghu7, Hui Zhuang8.   

Abstract

The Chinese Society of Hepatology developed the current guidelines for the Management of Ascites and Its Related Complications in Cirrhosis based on the published evidences and the panelists' consensus. The guidelines provided recommendations for the diagnosis and management of cirrhotic ascites emphasizing a step-wise approach with the first-, second-, and third-line therapy. For refractory ascites, vasoconstrictors and albumin are recommended for splanchnic vasodilation and selective vasopressin (V2) receptor antagonists for moderate-to-severe hyponatremia. For spontaneous bacterial peritonitis, empirical anti-infection treatment was recommended based on the local microbiological examination of community- or hospital-acquired infections. For hepatorenal syndrome, the administration of vasopressor terlipressin and albumin is recommended.

Entities:  

Keywords:  Ascites; Diagnosis; Guidelines; Hepatorenal syndrome; Liver cirrhosis; SBP; Therapy

Mesh:

Substances:

Year:  2019        PMID: 30656520     DOI: 10.1007/s12072-018-09923-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  83 in total

Review 1.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

2.  Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.

Authors:  Thomas D Boyer; Arun J Sanyal; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Veit Gülberg; Samuel Sigal; Alice S Bexon; Peter Teuber
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

Review 3.  Evolving Indications for Tips.

Authors:  Mitchell Smith; Janette Durham
Journal:  Tech Vasc Interv Radiol       Date:  2016-01-29

4.  EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2018-04-10       Impact factor: 25.083

5.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Authors:  Robert W Schrier; Peter Gross; Mihai Gheorghiade; Tomas Berl; Joseph G Verbalis; Frank S Czerwiec; Cesare Orlandi
Journal:  N Engl J Med       Date:  2006-11-14       Impact factor: 91.245

6.  The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial.

Authors:  Salvatore Piano; Silvano Fasolato; Freddy Salinas; Antonietta Romano; Marta Tonon; Filippo Morando; Marta Cavallin; Elisabetta Gola; Antonietta Sticca; Arianna Loregian; Giorgio Palù; Giacomo Zanus; Marco Senzolo; Patrizia Burra; Umberto Cillo; Paolo Angeli
Journal:  Hepatology       Date:  2015-08-04       Impact factor: 17.425

7.  Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.

Authors:  Lars Bossen; Aleksander Krag; Hendrik Vilstrup; Hugh Watson; Peter Jepsen
Journal:  Hepatology       Date:  2016-01-05       Impact factor: 17.425

8.  Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.

Authors:  Pere Ginès; Florence Wong; Hugh Watson; Slobodan Milutinovic; Luis Ruiz del Arbol; Dan Olteanu
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

9.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.

Authors:  Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

Review 10.  Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites.

Authors:  Lin-Lin Huang; Harry Hua-Xiang Xia; Sen-Lin Zhu
Journal:  J Clin Transl Hepatol       Date:  2014-03-15
View more
  12 in total

1.  [Etiology of ascites in 165 children].

Authors:  Yong Wang; Sheng-Hua Wan; Chun-Lei Zhan; Zhen-Jun Xiao; Xiao-Fen Liu; Na Li
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-04-15

2.  Spontaneous Fungal Ascites Infection in Patients with Cirrhosis: An Analysis of 10 Cases.

Authors:  Beiling Li; Chao Yang; Zhiping Qian; Yan Huang; Xianbo Wang; Guotao Zhong; Jinjun Chen
Journal:  Infect Dis Ther       Date:  2021-03-11

3.  Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study.

Authors:  Yang Yang; Sirui Fu; Bin Cao; Kenan Hao; Yong Li; Jianwen Huang; Wenfeng Shi; Chongyang Duan; Xiao Bai; Kai Tang; Shirui Yang; Xiaofeng He; Ligong Lu
Journal:  Hepatol Int       Date:  2021-05-11       Impact factor: 6.047

4.  Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.

Authors:  Xuan Wang; Wei Zhang; Ming Zhang; Feng Zhang; Jiangqiang Xiao; Qin Yin; Hao Han; Taishun Li; Ge Lin; Yuzheng Zhuge
Journal:  Hepatol Int       Date:  2022-01-12       Impact factor: 9.029

5.  The value of ascitic neutrophil gelatinase-associated lipocalin in decompensated liver cirrhosis with spontaneous bacterial peritonitis.

Authors:  Hua Liu; Ping Zhu; Caiyun Nie; Qing Ye; Yanying Gao; Huaiping Liu; Guoju Pang; Tao Han
Journal:  J Clin Lab Anal       Date:  2020-02-26       Impact factor: 2.352

6.  Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study.

Authors:  Xin-Yue Lv; Hui-Guo Ding; Jun-Fu Zheng; Chun-Lei Fan; Lei Li
Journal:  World J Gastroenterol       Date:  2020-01-14       Impact factor: 5.742

Review 7.  Chinese guidelines on the management of liver cirrhosis (abbreviated version).

Authors:  Xiao-Yuan Xu; Hui-Guo Ding; Wen-Gang Li; Jing-Hang Xu; Ying Han; Ji-Dong Jia; Lai Wei; Zhong-Ping Duan; En-Qiang Ling-Hu; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2020-12-07       Impact factor: 5.742

8.  Dynamic monitoring with shear wave elastography predicts outcomes of chronic hepatitis B patients with decompensated cirrhosis.

Authors:  Junzhao Ye; Yang Huang; Yanhong Sun; Congxiang Shao; Shenghong Zhang; Wei Wang; Bihui Zhong
Journal:  Ann Transl Med       Date:  2021-11

9.  Explainable machine learning model for predicting spontaneous bacterial peritonitis in cirrhotic patients with ascites.

Authors:  Yingying Hu; Ruijia Chen; Haibing Gao; Haitao Lin; Jinye Wang; Xiaowei Wang; Jingfeng Liu; Yongyi Zeng
Journal:  Sci Rep       Date:  2021-11-04       Impact factor: 4.379

10.  Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.

Authors:  Jieting Tang; Yongfeng Wang; Tao Han; Qing Mao; Jun Cheng; Huiguo Ding; Jia Shang; Qin Zhang; Junqi Niu; Feng Ji; Chengwei Chen; Jidong Jia; Xiangjun Jiang; Nonghua Lv; Yueqiu Gao; Zhenghua Wang; Zhong Wei; Yingxuan Chen; Minde Zeng; Yimin Mao
Journal:  BMC Gastroenterol       Date:  2020-11-19       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.